Effect of binary and ternary solid dispersions on the in vitro dissolution and in-situ rabbit intestinal absorption of gliclazide

Pakistan Journal of Pharmaceutical Sciences

Volumn 24, Issue 4, 2011, Pages 459-468

  El Maghraby, Gamal Mohamed ^a,b   Alomrani, Abdullah Hasan ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b TANTA UNIVERSITY   (Egypt)

Author keywords

Gliclazide; In situ; Intestinal absorption; P glycoprotein; Permeability

Indexed keywords

GLICLAZIDE; MACROGOL 6000; ORAL ANTIDIABETIC AGENT; POLOXAMER;

ANIMAL TISSUE; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG FORMULATION; DRUG SOLUBILITY; FOURIER TRANSFORMATION; IN VITRO STUDY; INFRARED SPECTROSCOPY; INTESTINE ABSORPTION; NONHUMAN; SOLID DISPERSION; THERMODYNAMICS; X RAY DIFFRACTION;

ADJUVANTS, PHARMACEUTIC; ANIMALS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; COLON; GLICLAZIDE; ILEUM; INTESTINAL ABSORPTION; JEJUNUM; MALE; PERFUSION; POLOXAMER; POLYETHYLENE GLYCOLS; RABBITS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; THERMODYNAMICS; TRANSITION TEMPERATURE; WATER; X-RAY DIFFRACTION;

EID: 80053442489     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Abou Auda HS, Bawazir SA, Asiri YA, Gubara OA and Al-Hadiya BM (2006). Studies on solubility, bioavailability and hypoglycemic activity of gliclazide b-cyclodextrin complexes. Int. J. Pharmacol., 2: 656-663. (Pubitemid 46242578)
2. Aggarwal S, Singh PN and Mishra P (2002). Study on the solubility and hypoglycemic activity of gliclazide beta-cyclodextrin hydroxypropylmethylcellulose complex. Pharmazie, 57: 191-193. (Pubitemid 34213912)
3. Al-Salami H, Butt G, Tucker I, Skrbic R, Golocorbin-Kon S and Mikov M (2008). Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats. Arch. Drug Info., 1: 35-41.
4. Biswal S, Sahoo J, Murthy PN, Giradkar KP and Avari JG (2008). Enhancement of dissolution rate of gliclazide using solid dispersions with polyethylene glycol 6000. AAPS PharmSci. Tech., 9(2): 563-570.
5. Brusewitz C, Schendler A, Funke A, Wagner T and Lipp R (2007). Novel poloxamer-based nanoemulsions to enhance the intestinal absorption of active compounds. Int. J. Pharm., 329: 173-181. (Pubitemid 44937529)
6. El Maghraby GM and Alomrani AH (2009). Synergistic enhancement of itraconazole dissolution by ternary system formation with pluronic F68 and hydroxypropylmethylcellulose. Sci. Pharm., 77: 401-417.
7. Ford JL (1986). The current status of solid dispersions. Pharm. Acta. Helv., 61: 69-88.
8. Harrower A., 1994. Comparison of efficacy, secondary failure rate and complication of sulfonylureas. J Diabetes Complications, 8, 201-203. (Pubitemid 24375625)
9. Hong SS, Lee SH, Lee YJ, Chung SJ, Lee MH and Shim CK (1998). Accelerated oral absorption of gliclazide in human subjects from a soft gelatin capsule containing a PEG 400 suspension of gliclazide. J. Control Rel., 51: 185-192. (Pubitemid 28252870)
10. Huang J, Si L, Jiang L, Fan Z, Qiu J and Li G (2008). Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. Int. J. Pharm., 356: 351-353.
11. Mailhot J (1993). Efficacy and safety of gliclazide in the treatment of non-insulin dependent diabetes mellitus: a Canadian multicenter study. Clin. Ther., 15: 1060-1068.
12. Moyano JR, Arias-Blanco MJ, Gines JM and Giordano F (1997). Solid-state characterization and dissolution characteristics of gliclazide-β- cyclodextrin inclusion complexes. Int. J. Pharm., 148: 211-217. (Pubitemid 27160978)
13. Osman MA, El Maghraby GM and Hedaya MA (2006). Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: Evidence for sitedependent absorptive clearance. Biopharm. Drug Disp., 27: 93-102.
14. Palmer KJ and Brogden RN (1993). Gliclazide - an update of its pharmacological properties and therapeutic efficacy in noninsulin- dependent diabetes mellitus. Drugs, 46: 92-125. (Pubitemid 23232408)
15. Patil MP and Gaikwad NJ (2009). Preparation and characterization of gliclazide-polyethylene glycol 4000 solid dispersions. Acta. Pharm., 59: 57-65.
16. Winters CS, York P and Timmins P (1997). Solid state examination of a gliclazide: beta-cyclodextrin complex. Eur. J. Pharm. Sci., 5: 209-214. (Pubitemid 27273944)
17. Wong SM, Kellaway IW and Murdan S (2006). Fast-dissolving microparticles fail to show improved oral bioavailability. J. Pharm. Pharmacol., 58(10): 1319-1326. (Pubitemid 44580562)
18. Mooter GV, Augustijns P, Blaton N and Kinget R (1998). Physicochemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K 30. Int. J. Pharm., 164: 67-80. (Pubitemid 28160099)
19. Shah TJ, Amin AF, Parikh JR and Parikh RH (2007). Process optimization and characterization of poloxamer solid dispersions of a poorly water soluble drug. AAPS PharmSci. Tech., 8(2): E1-E7.
20. Shavi GV, Kumar AR, Usha YN, Armugam K, Ranjan OP, Ginjupalli K, Pandey S and Udupa N (2010). Enhanced dissolution and bioavailability of gliclazide using solid dispersion techniques. Int. J. Drug Deliv., 2: 49-57.
21. Shewale BD, Fursule RA and Sapkal NP (2008). Effect of pH and hydroxylpropyl-β-cyclodextrin on solubility and stability of gliclazide. Int. J. Health Res., 1(2): 95-99.
22. Talari R, Varshosaz J and Nokhodchi A (2009). Dissolution enhancement of gliclazide using pH change approach in presence of twelve stabilizers with various physico-chemical properties. J. Pharm. Pharm. Sci., 12(3): 250-265.
23. Varshosaz J, Talari R, Mostafavi SA and Nokhodchi A (2008). Dissolution enhancement of gliclazide using in situ micronization by solvent change method. Powder Technology, 187: 222-230.